Back    Zoom +    Zoom -
CN 1Q26 Innovative Drug Licensing Transactions Top USD60B: NMPA
Recommend
26
Positive
48
Negative
14
In 1Q26, China saw the transaction amount for licensing innovative drugs exceed USD60 billion, nearly half of the total for the entire year of 2025, according to a report by CCTV, citing data released by the National Medical Products Administration (NMPA).

As of last Friday (27th), ten innovative drugs were greenlighted for sale this year, with two imported and eight domestically produced, a historic breakthrough in innovative drugs in China.

Related News UBS Lowers EPS Forecasts for WUXI BIO (02269.HK) for This and Next Year, Slightly Reduces TP to HKD49.3

AAStocks Financial News